Biểu đồ giá cổ phiếu MBRX
MBRX Cổ tức
Moleculin Biotech Inc
$2.2
2.8%
$0.06
Khi đóng cửa: May 14, 16:00:00 GMT-4
$2.26
2.97%
$0.06
Phiên trước giờ: May 15, 04:15:26 GMT-4
Quay lại
Moleculin Biotech Inc (MBRX) Cổ tức
Thống kê chính
Giá đóng cửa trước
$2.14
Giá mở cửa
$2.2
Phạm vi ngày
$2.17 - $2.26
Phạm vi 52 tuần
$1.79 - $28.61
Khối lượng
259.6K
Khối lượng trung bình
224.4K
Tỷ suất cổ tức
--
EPS (TTM)
-39.60
Vốn hóa thị trường
$12.0M
MBRX là gì?
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
